Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00389766
Status:
WITHDRAWN
Last Update Posted:
2013-07-10
First Post:
2006-10-18
Brief Title:
High-Dose Iodine I 131 Metaiodobenzylguanidine Topotecan and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
Sponsor:
Childrens Cancer and Leukaemia Group
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
International Phase II Studies of I-mIBG in Combination With Topotecan and Peripheral Blood Stem Cell Rescue for A Primary Resistant High Risk Neuroblastoma and B Relapsed Stage 4 Neuroblastoma
Status:
WITHDRAWN
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Withdrawn because protocol has been discontinued It was never opened
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radioisotope therapy such as iodine I 131 metaiodobenzylguanidine MIBG releases radiation that kills tumor cells Drugs used in chemotherapy such as topotecan work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing Topotecan may also make tumor cells more sensitive to iodine I 131 MIBG A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by iodine I 131 MIBG and topotecan This may allow more iodine I 131 MIBG and topotecan to be given so that more tumor cells are killed
PURPOSE This phase II trial is studying how well giving high-dose iodine I 131 MIBG together with topotecan and peripheral stem cell transplant works in treating young patients with relapsed stage 4 neuroblastoma or primary resistant high-risk neuroblastoma
PURPOSE This phase II trial is studying how well giving high-dose iodine I 131 MIBG together with topotecan and peripheral stem cell transplant works in treating young patients with relapsed stage 4 neuroblastoma or primary resistant high-risk neuroblastoma
Detailed Description:
OBJECTIVES
Determine response partial and complete response at metastatic sites in children with relapsed stage 4 neuroblastoma or primary resistant high-risk neuroblastoma treated with high-dose iodine I 131 metaiodobenzylguanidine topotecan hydrochloride and peripheral blood stem cell transplantation
Determine the proportion of patients who as a result of this treatment are able to progress to potentially curative surgery and further systemic treatment
Correlate tumor dosimetry to determine whether the tumor absorbed the radiation dose with response in patients treated with this regimen
Determine the time to tumor progression
OUTLINE This is an open-label multicenter study Patients are stratified according to disease type relapsed stage 4 vs primary resistant high-risk neuroblastoma
Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and 15-19 and high-dose iodine I 131 metaiodobenzylguanidine 131I-MIBG IV over 30 minutes on days 1 and 15 Patients receive autologous CD 34 peripheral blood stem cells when 131I-MIBG dosimetry levels reach an acceptable low on days 25-29
Total whole-body absorbed dose is measured periodically after the first 131I-MIBG dose is administered and periodically thereafter
After completion of study treatment patients are followed periodically for up to 10 years
PROJECTED ACCRUAL A total of 67 patients will be accrued for this study
Determine response partial and complete response at metastatic sites in children with relapsed stage 4 neuroblastoma or primary resistant high-risk neuroblastoma treated with high-dose iodine I 131 metaiodobenzylguanidine topotecan hydrochloride and peripheral blood stem cell transplantation
Determine the proportion of patients who as a result of this treatment are able to progress to potentially curative surgery and further systemic treatment
Correlate tumor dosimetry to determine whether the tumor absorbed the radiation dose with response in patients treated with this regimen
Determine the time to tumor progression
OUTLINE This is an open-label multicenter study Patients are stratified according to disease type relapsed stage 4 vs primary resistant high-risk neuroblastoma
Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and 15-19 and high-dose iodine I 131 metaiodobenzylguanidine 131I-MIBG IV over 30 minutes on days 1 and 15 Patients receive autologous CD 34 peripheral blood stem cells when 131I-MIBG dosimetry levels reach an acceptable low on days 25-29
Total whole-body absorbed dose is measured periodically after the first 131I-MIBG dose is administered and periodically thereafter
After completion of study treatment patients are followed periodically for up to 10 years
PROJECTED ACCRUAL A total of 67 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT-2005-002089-13 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000508611 | REGISTRY | None | None |
| EU-20644 | None | None | None |